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We have previously demonstrated that suppressor cells can abrogate 4-hydroxy-3- 
nitrophenyl acetyl (NP)l-specific delayed-type hypersensitivity (DTH)  responses (1- 
3). We now examine the ability of the same population of suppressor cells to abrogate 
cutaneous sensitivity (CS)  responses. Previous studies have noted several differences 
between  the  effector T  cell  populations  which  mediate  DTH  and  CS  (4-6).  In 
particular, DTH responses can be transferred between strains of mice sharing only 
the H-2I region of the murine major histocompatibility complex, in contrast to CS 
responses, where homology at either H-2K, I, or D  is sufficient for adoptive transfer 
of reactivity (4, 5).  Further, it has been demonstrated that T  cells mediating H-2I- 
restricted and H-2D-restricted immune responses may bear different idiotypic recep- 
tors (6, 7). 
Recognizing the importance of idiotypic-anti-idiotypic interactions in the genera- 
tion of antigen-specific immune suppression (3, 8), we now extend the comparison of 
DTH and CS responses by analyzing the mechanisms of suppression of CS reactions. 
Earlier investigations have implicated the involvement of two distinct T  cells from 
the NP-tolerized lymphocyte population in the regulation of DTH immunity (1-3): 
induction-phase suppressor T  cells (Ts  ~ or Tsx), which can be generated by antigen 
alone; and effector-phase suppressors (Ts  e or Ts2), which depend for their generation 
on both antigen and Ts  i or idiotype-positive factor derived from Ts  i. Recent evidence 
in another system (9) has further suggested the requirement of a third auxiliary T cell 
from the immune lymphocyte population for the suppression of 2,4-dinitro-1-fluoro- 
benzene  (DNFB)  contact sensitivity by Ts  e. The current study unifies and extends 
these findings, demonstrating in a single system the development of all three suppressor 
cell types after in vivo antigen administration. 
Materials and Methods 
Mice.  All mice were either purchased from The Jackson Laboratory, Bar Harbor, Maine, 
or bred in the animal facilities at Harvard Medical School, Boston, Mass.  Mice were used at 
* Supported by grants AI-00152 and AI-16677  from the National Institutes of Health and grant PCM- 
80-04573  from the National Science Foundation. 
Abbreviations used in this paper: BBS, borate-buffered saline; C, complement; CS, cutaneous sensitivity; 
DMSO,  dimethyl sulfoxide; DNFB, 2,4-dinitrofluorobenzene; DTH,  delayed-type hypersensitivity; lgh, 
immunoglobulin heavy chain-determining region; LN,  lymph node; MEM,  Eagle's minimum essential 
medium;  NP,  (4-hydroxy-3-nitrophenyl) acetyl;  NP-O-Su,  NP-O-succinimide;  PBS,  phosphate-buffered 
saline; T..x or Tsa,  third-order "auxiliary" suppressor T  cell;  Ts  e or Ts2, second-order "effector-phase" 
suppressor T cell; Ts  i or TSl, first-order 'induction-phase' suppressor T cell. 
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1.5 to 12 mo of age, and were maintained on laboratory chow andacidified, chlorinated water 
ad lib. 
Antigens.  NP-O-succinimide (NP-O-Su)  was  purchased  from  Biosearch  Co.,  San  Rafael, 
Calif.  DNFB  was  obtained  from  Sigma  Chemical  Co.,  St.  Louis,  Mo.  Dimethylsulfoxide 
(DMSO) was purchased from Fisher Scientific Co., Medford, Mass. 
Immunization and Elicitation of CS Responses.  Animals were shaved and primed subcutaneously 
with a saturated solution of NP-O-Su (7 g/100 ml) in DMSO. A total of 0.1  ml of antigen was 
divided equally between two sites on each ventral flank, followed by 0.1 ml of borate-buffered 
saline (BBS)  at  pH 8.6.  6  d  after  immunization or  1-2 h  after adoptive transfer, mice were 
challenged for the CS response as described previously (5).  In brief, 25 #1 of NP-O-Su  (0.1% 
solution in phosphate-buffered saline [PBS]) was injected into the left footpad. Footpad swelling 
was  measured  24  h  after  challenge using an engineer's micrometer  (Schlesingers for Tools, 
Brooklyn, N. Y.). Responses were determined as the difference, in units of 10  -3 cm, between the 
left and right footpad thickness. 
For specificity testing, animals were sensitized with two daily paintings of 25/11 0.5% DNFB 
in a 4:1 mixture of acetone and olive oil, as previously described (9). 5 d after the last painting, 
20 pl 0.2% DNFB in the same vehicle was applied to the dorsal surface of the ear, and the ear 
swelling response was measured as the difference between right and left ear thickness at 24 h~ 
Haptenated Cell Preparation.  NP-coupled spleen cells were made as described previously (1). 
Briefly, single cell suspensions were  treated  with Tris-NHsCI to lyse erythroeytes.  After two 
washes,  the cells were  resuspended  in PBS, pH  7.7,  and reacted  with  2.5 mM  NP-O-Su in 
DMSO for 4 min. The reaction was stopped with Eagle's minimum essential medium (MEM) 
containing 1.2 mg/ml glycylglycine. After extefisive washing in MEM,  4  ×  10  v NP-coupled 
cells were injected into syngeneic recipients. 
Antisera and Antibody Treatments.  6-7 ×  108 spleen cells from NP-coupled-cell-treated mice or 
NP-immune lymph node (LN) cells were pelleted and incubated in 1.0 ml of a  1:5 dilution of 
AKR  anti-C3H thymocyte antiserum  (anti-Thy-l.2), B10.A(3R)  ahti-B10.A(SR)  (anti-I-Jk), 
B10.A(5R) anti-B10.A(3R) (anti-I-Jb), or as a  control, normal mouse serum (NMS). After 30 
rain at 20°C, cells were washed and resuspended in 1.0 ml rabbit complement (C) diluted 1:5 
in RPMI-1640 containing 1% DNase. After a 30-min incubation at 37°C, cells were washed in 
RPMI-1640 before transfer. 
Adoptive Transfer of Suppression.  4  X  10  7 viable spleen cells from mice that had received NP- 
coupled spleen cells 6 d earlier were transferred intravenously into recipient mice either on day 
0 (induction phase) or on day 6 (effector phase), 1 h before either antigen priming or challenge. 
Control  groups  received  normal  spleen  cells.  CS  responses  were  elicited  and  measured  as 
described above. Percent suppression is calculated as: 
(control response -  experimental response) 
% =  ×  I00. 
(control response -- background) 
Double Adoptive Transfer of CS Effector Cells and Ts e.  Mice were immunized as described above. 
6 d  after priming, the animals were killed, inguinal lymph nodes were removed, and a single 
a  fine mesh screen. After washmg, 4.0 ×  10  vtable cells  cell suspension was prepared  using  •  7  • 
were treated with antiserum plus C  and mixed in a test tube with 4 ×  10  7 NP-tolerized spleen 
cells or control normal spleen cells immediately before intravenous transfer into naive syngeneic 
recipients. In several groups of mice, 1 ×  10  7 NP-immune LN cells were added to the mixture 
before transfer (see Table IV). Recipients and control mice were challenged with NP-O-Su 1 h 
after transfer, as describe above. 
Data Analysis.  Two-tailed Student's t tests were used to perform statistical analyses. Data 
are expressed as the mean incremental footpad or ear swelling :1: SE in units of 10  -3 cm. 
Results 
Phenotype  of  Splenocytes  Responsible  for  Suppression  of  Syngeneic  NP-specific  CS 
Responses.  Splenocytes  from  B10.BR  congenic  mice  were  depleted  of erythrocytes 
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injected  intravenously  into  6-8-wk-old  syngeneic  recipients.  6  d  later,  4  ×  107 
splenocytes from these mice (termed NP-tolerized spleen cells) or control spleen cells 
from  normal  mice were  transferred  intravenously into syngeneic mice at  either  the 
induction or effector  phase  of NP-specific  CS  responses.  As shown  in Table  I,  NP- 
tolerized  spleen cells  (Ts),  but  not control  normal splenocytes, are capable of com- 
pletely suppressing NP-CS  responses  at  both  the  afferent  and  efferent  limbs of the 
immune  response. 
T  cells are required  for the transfer of NP-nonresponsiveness as demonstrated  by 
total abrogation of Ts activity by anti-Thy-1.2 antiserum plus C, as seen in Table I, 
experiment  1. Anti-I-J antiserum plus C  was similarly able to lyse specifically both Ts 
populations for CS responses, as indicated by the results in experiments 2 and 3. The 
specificity of the anti-I-J  k alloantiserum was demonstrated by its failure to eliminate 
Ts cells obtained from R106 mice that carry the I-J  b allele. 
Furthermore, treatment of Ts with anti-Lyt-2.2 hybridoma antibody plus C  showed 
that the effector-phase suppressor cells are Lyt-2.2 positive (data not shown). However, 
this same treatment only partially abrogated the activity of induction-phase suppres- 
sors;  thus,  we  cannot  unequivocally  determine  the  Lyt-2  phenotype  of  the  Ts  i 
population  (data  not shown).  In conclusion, both  the induction- and effector-phase 
suppressor cells are I-J-bearing T  cells, but they may differ in their susceptibility to 
anti-Lyt-2 treatment. 
Specificity  of NP-induced  Suppressor  Cells.  We  then  proceeded  to  determine  the 
antigen specificity of NP-tolerized spleen cells at  the effector phase of CS responses. 
TABLE  I 
Phenotype of Splenocytes Suppressing Syngeneic NP-specific CS Responses* 
Experi-  Strain  Treatment of transferred 
ment  cells 
Time of Ts administration~: 
Induction phase  Effector phase 
1  BI0.BR 
2  BIO.BR (I-J k) 
3  RI06 (I-J  u) 
Control cells  26.5 :t: 2.3 (6)§  26.4 ±  1.8 (7)§ 
Ts + NMS + C  12.0:1:1.8  (6)  13.2 ±  1.5 (6) 
Ts + anti-Thy-l.2 + C  25.8 +  3.0 (4)11  29.2 :lz 1.7 (6)11 
Control ceils  26.5 ± 2.5 (6)§  27.6 ±  2.2 (8)§ 
Ts +  NMS + C  13.8 ±  1.8 (5)  15.5 ±  1.4 (4) 
Ts + anti-I-J  k + C  22.4 :t: t.8 (5)11  25.8 :t: 1.6 (5)11 
Control cells  24.2 :!: 1.3 (6)§  32.4 +  2.7 (5)§ 
Ts+NMS+C  11.0:1:1.1  (4)  16.3+2.3(6) 
Ts + anti-I-J  k + C  8.8 ±  1.8 (5)  17.2 ±  1.6 (6) 
Ys + anti-I-J  b + C  26.8 _  1.9 (4)11  29.0 ±  2.3 (5)11 
* On day 0, mice were immunized with NP-O-Su (7 g/100 ml in DMSO) given subcutaneously on both 
flanks. 4 ×  10  7 syngeneic NP-tolerized spleen cells were treated as indicated and transferred  intravenously 
either on day 0  (induction phase)  or on day 6 (effector phase) one h before NP-O-Su administration. 
Control groups received normal spleen cells. On day 6, mice were challenged in one footpad with NP-O- 
Su (0.1 g/100 ml). CS responses were measured 24 h later as the difference between the right and left 
footpad  thickness. 
Responses expressed as the mean incremental footpad  swelling in units of 10  -a cm ±  1 SE. Number of 
mice per group in parentheses. 
§ P <  0.007 as compared with nonimmune mice challenged with NP-O-Su. Background footpad swellings 
measured 12.8 ± 0.9 U (5). 
IIP <  0.01 compared with immune mice receiving NP-tolerized  spleen cells treated with NMS or medium 
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Mice were immunized with NP-O-Su and/or DNFB, followed 6 d later by intravenous 
transfer of NP-tolerized spleen cells or control splenocytes immediately before chal- 
lenge  in  the  footpad  with  NP-O-Su  or  on  the  ear  with  DNFB.  Responses  were 
measured at 24 h  as the incremental swelling between right and left (footpads or ear 
pinnae, respectively). The data are summarized in Table II. It is apparent that NP- 
tolerized spleen cells given intravenously are able to suppress NP-O-Su-induced, NP- 
O-Su-elicited CS  responses to  background levels, but  have  no significant effect  on 
DNFB-primed, DNFB-elicited swelling. Further, when mice are sensitized with both 
NP-O-Su and DNFB, NP-tolerized spleen ceils are still unable to  suppress  DNFB- 
specific immunity under the conditions used. Thus, NP-induced effector suppressor 
cells inhibit CS effector cells in an antigen-specific manner. 
Genetic Restrictions of Effector-Phase Suppressor Cells.  Next, we investigated the genetic 
restrictions on NP-induced effector-phase suppressor cell activity, using B 10.BR mice 
as the Ts donors. The results of these studies are presented in Table III. It is clear that 
NP-tolerized Ts  from  B10.BR  mice  inhibit syngeneic NP-specific CS  responses  to 
within background levels. In contrast, B10.BR Ts have no discernible effect on CS 
reactions in B10  mice, which are congenic with B10.BR  at  the  H-2 complex. This 
implies the presence of an H-2 restriction between the Ts  e donor and recipient. 
Further, "Is  e from BI0.BR mice are unable tO suppress NP-specific CS responses in 
C3H  mice, which share the H-2  k haplotype with B10.BR but differ at  background 
loci. In contrast, B10.BR Ts are able to inhibit NP-O-Su CS responses in CKB mice, 
which are congenic with C3H at  the Igh region. These results, which implicate the 
involvement of allotype-linked genes in the activity of effector-phase Ts, have been 
confirmed  in  several  experiments using different  strain  combinations. Thus,  both 
H-2 and Igh-linked loci apparently have a role in the mechanism of action of effector- 
phase Ts for NP-specific CS responses. 
Phenotype  of  Third  Cell  Population  Involved  in  Suppressor Pathway.  To  extend  our 
TABLE  II 
Specificity of NP-induced Suppressor Cells* 
Cells transferred  Immunogen 
Response~ 
NP-O-Su (foot- 
pad)  DNFB (ear) 
Control spleen cells  NP-O-Su  21.6 2:1.1 (5)§  NT 
NP-tolerized spleen cells  NP-O-Su  10.3 +  1.3 (6)11  NT 
Control spleen cells  DNFB  NT¶  6.7 +  1.4 (20)§ 
NP-tolerized spleen cells  DNFB  NT  7.0 2:1.4 (20)§ 
Control spleen cells  NP-O-Su + DNFB  26.0 2:2.8 (5)§  7.0 ± 0.8 (22)§ 
NP-tolerized spleen ceils  NP-O-Su + DNFB  6.8 2:1.5 (5)11  5.8 2:1.1 (22)§ 
None  None  7.8 2:1.1 (5)  0.5 2:0.2 (2H 
* B10.HTT mice were sensitized either with NP-O-Su (7 g/100 ml DMSO) injected subcutaneously on 
both flanks on day 0, and/or with DNFB (0.5% in olive oil:acetone [1:4]) painted on the ventral surface 
on days 0 and 1.6 d later, NP-tolerized spleen cells or control cells were transferred. 1 h after transfer, 
mice were challenged by the injection of one footpad with NP-O-Su and/or the painting of one ear with 
DNFB. Responses were measured at 24 h as the difference between right and left footpad or ear pinna 
thickness. 
:~ Responses expressed as the mean incremental swelling 2:1 SE in units of 10  -3 cm. 
§ P < 0.05 compared with nonimmune  mice challenged with the same agent. 
IIP < 0.001 compared with immune mice receiving  control spleen cells. 
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TABLE  III 
Genetic Interactions of B I O.BR Effector-Phase Suppressor Cells* 
Recipient 
Strain  H-2  Igh- I 
Spleen cells 
transferred  Footpad response:~ 
B10.BR  k  b  Control  23.8 2:1.4 (5)§ 
Ts  13.6 2:1.4 (5)11 
B10  b  b  Control  24.6 2:1.7 (7)§ 
Ts  25.3 2:2.4 (6)§ 
C3H  k  j  Control  33.3 2:2.5 (4)§ 
Ts  33.0 2:4.8 (4)§ 
CKB  k  b  Control  31.0 -  1.0 (5)§ 
Ts  12.0 2:2.9 (5)1  { 
* See legend to Table I for protocol. 
:~ Res]3onses expressed as the mean incremental footpad swelling in units of 
10-  cm 2: SE. Number of mice per group in parentheses. 
§ P  <  0.0001  compared  with  nonimmune mice challenged with  NP-O-Su, 
which gave background swellings of 10.9 2:0.9 (17). 
I[ P  <  0.0007  compared with immune mice receiving control normal spleen 
cells. 
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TABLE  IV 
Phenotype of Third Cell Involved m Suppressor Pathway* 
Percent 
Treatment of CS  Effector-phase suppres-  Treatment of Tss  Footpad response:~  suppres- 
effector cells  sor cells  cells  sion 
NMS +  C  Control cells  No cells  24.7 2:1.4 (6)§  0 
NMS +  C  NP-tolerized ceils  No cells  11.3 2:1.4 (9)ll  85 
Anti-I-J +  C  Control cells  No cells  26.3 2:1.5 (6)§  0 
Anti-l-J +  C  NP-tolerized cells  No cells  23.5 2:2.0 (6)§  6 
Anti-I-J +  C  Control cells  NMS +  C  8.4 2:1.6 (5)[1  103 
Anti-I-J +  C  NP-tolerized cells  Anti-Thy-I +  C  22.8 2:0.8 (4)§  20 
* On day 0, donor mice were immunized subcutaneously with NP-O.Su. On day 6, the immune LN cells 
were harvested and treated with antiserum followed  by complement, as indicated. 4 ×  107 LN cells were 
mixed with 4 ×  10  7 NP-tolerized spleen cells or control normal spleen cells, with or without additional 
immune LN cells.  I  h  after intravenous transfer of cell  mixtures into syngeneic recipients, mice were 
challenged in one footpad with NP-O-Su and responses were measured 24 h later. 
~: Responses expressed as the mean incremental footpad swelling in units of 10  -3 cm 2: SE. Number of mice 
per group in parentheses. 
§ P <  0.0001 compared with control mice without cell transfer, receiving NP-O-Su challenge alone, which 
gave background swellings  of 8.9 +  1.2 (10). 
11 P <  0.0002  compared with mice receiving immune cells together with control spleen cells. 
knowledge  of suppressor  cell  interactions  occurring  at  the effector  phase  of NP  CS 
responses, the NP-O-Su  immune  LN  cell population  was  treated with anti-I-J antise- 
rum  plus C  before mixing and  transfer, together with NP-tolerized Ts or with control 
normal  cells into syngeneic recipients.  It  is apparent  from  the data  in Table  IV that 
NP-immune  cells treated with either NMS  or anti-I-J serum  plus C,  then transferred 
along with normal  spleen cells,  give rise to significant levels of footpad  swelling.  NP- 
tolerized  cells  were  able  to  suppress  almost  completely  the  immune  LN  population 
that  had  been  pretreated  with  NMS  plus C,  but  had  little,  if any,  suppressive effect 
on the same immune  LN cell populations  treated with anti-I-J serum  plus C. 
We  initiated  a  series of reconstitution  experiments  to  determine  the phenotype  of 816  SUPPRESSOR CELL  PATHWAYS IN CUTANEOUS SENSITIVITY 
the cell present  in  the  immune  cell population  that  was  required  for the  activity of 
NP-effector  suppressor  cells.  To  a  mixture  of 4  X  10 v anti-I-J-treated  NP-immune 
cells and  4  ×  107  NP-tolerized Ts were added  1 ×  107  viable syngeneic NP-immune 
LN cells that  had  been treated  beforehand  with NMS  plus C. As indicated  in Table 
IV,  this  small  number  of NMS-treated  immune  cells  was  able  to  reconstitute  the 
ability of Ts to inhibit  the entire NP-specific CS response. The cell required to restore 
suppression  was a  T  cell because treatment  of the immune  LN population  with anti- 
Thy-1.2  plus C  abrogated  the ability to restore immune  suppression.  In this manner, 
we  have  established  the  requirement  for  a  third  I-J-bearing  T  cell,  present  in  the 
immune  cell  population,  for  successful  function  of the  suppressor  cell  circuit.  This 
third cell population  will be termed Tsa. 
Tsa Suppressor Cells Are Sensitive to Cyclophosphamide.  To determine whether  the Tsa 
suppressor cell population present  in the immune  animal is sensitive to cyclophospha- 
mide,  recipient  mice were primed  subcutaneously  with  NP-O-Su  on  day  0,  followed 
24 h  later with either saline or 20 or 50 mg/kg  cyclophosphamide  injected intraperi- 
toneally.  On  day 6,  these mice received either 4  ×  107 NP-Ts e or control spleen cells 
from  syngeneic  donors.  It  is evident  from  the  data  in  Table  V  that  neither  dose  of 
cyclophosphamide  significantly altered  the level of the CS footpad swelling response 
in the groups  receiving control splenocytes.  However, treatment  of immunized  recip- 
ients with either 50 or 20 mg/kg  cyclophosphamide  abrogated the ability of syngeneic 
Ts  e to transfer suppression.  Further, reconstitution of these cyclophosphamide-treated 
immune  mice  with  10  v  NP-O-Su-immune  LN  cells  at  the  time  of  Ts  e  transfer 
completely  restored  suppression.  Finally,  107  LN  cells  from  syngeneic  mice  treated 
TABLE  V 
Ts3 Suppressor Cells Are Sensitive to Low-Dose Cyclophosphamide* 
Syngeneic Tsa 
Cytoxan  Spleen cells 
dose  transferred  Cells  Cyclophospha-  Footpad response:~ 
added  mide 
mg/kg 
None  Control  None  None  31. l +  1.5 (21)  § 
None  Ts  e  None  None  12.6 --- 0.8 (15)1  [ 
50  Control  None  None  32.5 +  1.6 (20)§ 
50  Ts  e  None  None  30.2 :t: 1.4 (16)§ 
20  Control  None  None  30.9 +  1.6 (7)§ 
20  Ts  e  None  None  29.0 +  4.9 (3)§ 
50  Ts  e  10  7  None  13.0 +-- 1.9 (4)11 
50  Ts  e  10  7  50 mg/kg  30.7 +  5.2 (3)§ 
* Recipient mice were primed subcutaneously with NP-0LSu on day 0, followed 24 h 
later with an intraperitoneal injection of either saline or cyc[ophosphamide  in saline 
at  the  indicated  dosages.  On  day  6,  these mice received  4  ×  107 syngeneic  NP- 
tolerized spleen cells or control normal spleen cells, with or without  107 additional 
LN cells from syngeneic  mice primed with NP-0-Su on day 0 with or without 50 
mg/kg cytoxan on day  1.  Mice were challenged with NP-0-Su  1 h after transfer 
and responses were measured at 24 h. 
:~ Responses  expressed  as the mean incremental footpad swelling in units of 10  -a cm 
+  1 SE.  Results from  three experiments have been  pooled.  Number of mice per 
group in parentheses. 
§ P <  0.005 compared with nonimmune mice without ceil transfer,  receiving NP-O- 
Su challenge alone, which gave background swellings of 9.8 +  1.4 (16). 
I1 P <  0.002 compared wilh immune mice receiving control  spleen cells. MARY  E.  SUNDAY,  BARUJ  BENACERRAF,  AND  MARTIN  E.  DORF  817 
with  50  mg/kg  cyclophosphamide  1  d  after  NP-O-Su  priming  were  unable  to 
reconstitute suppression. 
Genetic Restriction  of Tse-Tsa Interaction.  To  evaluate  the  genetic  requirements  for 
effective  Tse-Tsa  interaction,  NP-immune  recipient  mice  treated  with  50  mg/kg 
cyclophosphamide  on  day  1  were  subsequently  given  4  X  107  syngeneic  NP-Ts" 
together with Tsa from various inbred strains of mice. As shown in Table VI, syngeneic 
Tsa  from  NP-O-Su-immune  donors  are  able  to  reconstitute  suppression  in  both 
B 10.A(5R)  and B 10.BR mice. This reconstitution depends on specific antigen priming 
of the Ts3 donors, because DNFB-imnmne  LN  cells are unable  to restore suppression 
of NP-specific  CS  responses,  as  indicated  for  B10.BR  recipients.  Cyclophosphamide 
treatment  of syngeneic  Ts3  donors  abrogates  the  restorative  capacity  of NP-O-Su 
immune  LN  cells, as shown  for 5R  mice  (Table VI). 
The  H-2 restriction between Ts~-Ts3 interactions was demonstrated  by the inability 
of immune  LN  ceils  from  B10.HTG  mice,  which  are  congenic  with  5R  recipients 
(differing  at  the  H-2K,  H-2I,  and  H-2D  regions)  to  reconstitute  suppression.  This 
H-2 restriction was subsequently  mapped  to H-2I, as shown by the ability of Ts3 from 
B10.MBR  mice to restore suppression  in B10.BR  recipients.  Although  it is necessary 
for  suppression,  the  H-2  homology  requirement  alone  is  not  sufficient  for  effective 
Tse-Tsa  interaction.  It  is  clear  that  C3H  Tss  (H-2  k,  Igh-1 j)  are  unable  to  restore 
TABLE  VI 
Genetic Restriction of Tse-Tsa Interaction* 
Ts~-Ts3 homology  Percent 
NP-O-Su-  Syngeneic  Source of Ts3  suppres- 
primed recipient  Ts*  H-2  Igh  sion~ 
5R 
BI0.BR 
--  --  --  --  0 
+  --  --  -  25 
+  5R  K, I, S, D  +  95{} 
+  5R (CY)I  [  K, I, S, D  +  5 
+  BI0.| ITG  LC, S  +  5 
+  BI0.ItTG (CY)]I  LC, S  +  i5 
--  --  --  --  0 
+  --  --  -  19 
+  BI0.BR  K, I, S, D  +  96§ 
+  B10.BR (DNFB)¶  K, I, S, 1)  +  15 
+  B10.MBR  I, S  +  100§ 
+  CKB  K, I, S, D  +  100§ 
+  C3tt  K, I, S, D  None  31 
+  C57BL/6  None  +  27 
+  (B6 X C3H)F1  K, [, S, D  +  104§ 
* Recipient mice were primed subcutaneously with NP-O-Su on day 0, followed 24 h later with 50 mg/kg 
cyctophosphamide  injected  intraperitoneally. On  day 6,  these mice  received 4  X  I07  syngeneic NP- 
tolerized spleen cells (Ts  ~) or control spleen cells, with or without  107 additional I,N cells (Tsa) from the 
donor strains indicated. These Tsa donors were immunized with NP-O-Su on day 0, except for two groups 
(see footnote ~). Recipient mice were challenged with NP-O-Su  1 h  after transfer, and responses were 
measured at 24 h. 
:~ Percent suppression was calculated as in Materials and Methods. Actual footpad swelling responses,  in 
units of 10  -a em -- 1 SE (with 3-7 mice per group), were 32 4- 2 (5R) and 38 +  2 (B10.BR).  Nonimmune 
mice receiving NP-O-Su challenge alone gave background swelling of 12 +  1 (5R) and 7 4- 3 (B10.BR). 
§ P <  0.0002 compared with immune mice receiving control cells. 
II Tsa donors received 50 mg/kg cyclophosphamide 24 h after NP-O-Su immunization. 
¶ Tsa donor immunized with DNFB skin painting on day 0 and day  t  (inslead of NP-O-Su injection). 818  SUPPRESSOR  CELL  PATHWAYS  IN  CUTANEOUS  SENSITIVITY 
suppression in B 10.BR recipients (H-2  k, Igh-lb). However, NP-immune LN cells from 
CKB mice (H-2  k, Igh-lb), which are congenic with C3H at the Igh region, are fully 
able to restore suppression in B 10.BR mice. Thus, the Tse-Tsa interaction is governed 
by genes closely linked to both the Igh and the H-2 gene complexes. The dual genetic 
requirement is further supported by the ability of Ts3 from (C57BL/6 ×  C3H)F1 mice 
to restore suppression to B 10.BR recipients, although neither parental strain possesses 
this capability, due to lack of either H-2 (i.e., C57BL/6) or Igh (i.e., C3H) homology. 
In conclusion, the Tse-Ts8 interaction depends on specific antigen priming of Tsa and 
is restricted by both H-2I and Igh complex-linked genes. 
Discussion 
Intravenous administration of hapten-coupled syngeneic cells induces tolerance in 
a variety of experimental systems (1, 8-12). In these models, tolerance is mediated by 
suppressor T  lymphocytes. Similarly, in  the  present  experiments, spleen cells  from 
mice that had received NP-coupled syngeneic cells inhibited NP CS responses. As was 
previously demonstrated for NP-specific DTH responses (1, 3), the Ts can function at 
either  the  induction  or effector phases  of the  CS  response.  The cells  that  transfer 
suppression are T  lympocytes, because anti-Thy-l.2 antiserum plus C  abrogated the 
inhibitory capacity of the suppressor cells in both the induction and effector phases 
(Table I). In addition, both populations bear I-J determinants, although we do not 
know whether these cells bear identical or distinct I-J determinants. Preliminary Lyt 
phenotyping  indicated  that  at  least  the  Ts  e population  carries  the  Lyt-2  marker. 
Weinberger et al. (2) have demonstrated that the suppressor cells that function during 
the  induction  phase  can  be  distinguished  from effector-phase suppressors  by their 
ability to bind antigen or idiotype. 
Ts inhibit only NP-directed CS responses, and have no discernible effect on contact 
sensitivity to DNFB  (Table II).  Specificity was observed even when mice had been 
sensitized with both DNFB and NP-O-Su, and were challenged with both DNFB and 
NP-O-Su  in  the  presence  of NP-induced  Ts.  In  the  latter  case,  DNFB  contact 
sensitivity responses were not inhibited, whereas NP CS reactions in the same mice 
were significantly depressed. Thus, Ts are triggered to exert suppression on NP-CS- 
reactive cells in an antigen-specific manner. These data do not rule out the possibility 
that  Ts may act by elaborating nonspecific suppressor factors, which are known to 
operate both in vivo and in vitro (12-15), but which may only function across short 
distances and consequently would be unable to suppress  immune responses at sites 
distant from the area of specific antigen challenge. 
The strain specificity of the effector Ts was then investigated. It is apparent  from 
the results presented in Table III that a dual requirement exists for both H-2 and Igh 
compatibility between Ts  e donor and antigen-primed recipient for successful transfer 
of effector-phase suppression.  This conclusion is compatible with  findings  in  other 
experimental  models  (2,  8,  15-17),  and  is  important  to our understanding  of the 
cellular interactions involved, as will be described in more detail below. 
A previous report (9) suggested the participation of an additional T  cell in DNFB 
contact sensitivity suppressor circuits. Originally termed Taux, this cell was detected in 
the  lymphoid cells of the  antigen-primed  recipient.  Thus,  we  sought  to  determine 
whether an analogous cell is required for the function of NP-specific suppressors for 
NP  CS  responses.  As  the  results  in  Table  IV  indicate,  the  third  cell  population MARY E. SUNDAY, BARUJ BENACERRAF, AND MARTIN E.  DORF  819 
involved  in  this  suppressor  network  is  an  I-J-bearing  T  cell.  Again,  we  have  no 
evidence to suggest that this I-J is either identical to or distinct from I-J determinants 
on Ts  i and Ts  e populations, nor is it clear whether the I-J determinants are functionally 
involved in the suppressive mechanism. We have demonstrated that the Ts  e interac- 
tion is restricted by genes in the H-2I region (Table VI), which suggests a possible role 
for matching of  structures encoded within the I subregions. In other models, suppressor 
cells have been found bearing I-J determinants (10,  18), as well as elaborating soluble 
suppressor factors bearing I-J  determinants  (8,  13,  15),  which  have been shown  to 
mediate interactions between T  cell subpopulations.  Moreover, such suppressor cell 
interactions have been demonstrated to be I-J or I-C restricted in different systems 
(13,  14).  Although  we have not  shown the operation of such  factors in the NP CS 
model, this remains a  viable explanation for the requirement for H-2I compatibility 
between  the  I-J-bearing  Ts  ~ and  Tsa  suppressor  cell  populations.  Moreover,  our 
experiments  clearly  indicate  that  the  Ts3  population  is  sensitive  to  low  doses  of 
cyclophosphamide (Table V). This result appears to contrast with the data of Sy et 
al.  (9),  who claimed  that  the  Taux population  is  only sensitive to  higher  doses  of 
cyclophosphamide.  However,  in  that  model,  cyclophosphamide  was  given  2-3  d 
before  immunization,  whereas  we  injected  cyclophosphamide  1  d  after  NP-O-Su 
primings.  Considering the short  half-life of cyclophosphamide (19), it is likely that 
immune  cell  populations  in  both  models  are  exposed  to  the  same  range  of drug 
concentrations  during  the  maturation  period  after  sensitization.  Hence,  we  are 
probably describing a similar auxiliary suppressor population. More recently, transfer 
of fowl y-globulin-specific suppression  also has been shown  to depend on low-dose 
cyclophosphamide-sensitive cells in  immunized  recipient mice  (10), which suggests 
evidence for the  involvement of an  auxiliary suppressor population  in  yet another 
model. 
Thus, at least in the NP system, the Ts  i and Ts3 populations appear phenotypically 
similar  in  that  both  bear I-J  determinants and  their generation is  sensitive to low 
doses of cyclophosphamide (3). In addition, the Igh restriction noted between the Ts  e 
and Ts3 populations suggests that the Ts~ population may bear idiotypic determinants 
similar, if not identical, to those previously demonstrated on the Ts  i population (1). 
If this is indeed the case, our findings support many elements of the network theory 
of immunoregulation  (20). Experiments are in progress to further characterize these 
cell populations. 
The present study unifies and extends the results of many previous investigations 
into mechanisms of immunosuppression. Various studies have shown that at least two 
T  cell subpopulations must interact to generate antigen-specific suppression  (13,  17, 
21-23). Tada  (13)  reported the requirement of an Lyt-l+2+3  +, I-J  +, factor acceptor 
cell  for  suppression  of T  helper  cells,  implying  the  existence of T-T  interactions 
between a  suppressor-factor-producing T  cell and a separate suppressor T  cell from 
antigen-primed mice. This requirement for an antigen-primed I-J-bearing acceptor 
cell is consistent with evidence reported here and elsewhere (9, 10) for specific antigen- 
driven Ts~-Ts3 interactions. The Igh gene restriction demonstrated in several suppres- 
sor cell systems (2, 8,  17) is probably a consequence of idiotype-anti-idiotype interac- 
tions, as was previously detailed for suppression of NP-specific DTH response (3) and 
of NP-specific plaque-forming cell responses  (24).  Further,  the Igh  gene restriction 820  SUPPRESSOR CELL PATHWAYS IN CUTANEOUS SENSITIVITY 
between idiotype-specific Ts  ~ and the immune lymphocyte population suggests that 
the Tss population probably bears idiotypic determinants. 
Therefore, based on cumulative findings in both the NP DTH and NP CS systems, 
we now propose a  unifying hypothesis for a  mechanism of immunosuppression after 
antigen  exposure,  as  schematically depicted  in  Fig.  1.  Antigen-coupled  spleen  cells 
trigger  the  proliferation  of a  cyclophosphamide-sensitivity,  I-J-bearing,  induction- 
phase suppressor T  cell, termed Ts i or Tsl  in other systems, which has been shown to 
carry  an  idiotypic,  antigen-binding  receptor  (13).  Together  with  antigen,  the  Ts i 
population  induces  the  generation  of I-J  +  effector-phase suppressors  (Ts  ~ or  Ts2), 
which carry the corresponding anti-idiotypic receptor (3). Although the Ts  e population 
is active during the effector phase of the CS response, it is not the final effector cell. 
FIG.  1.  Irnmunoregulation of NP-induced T cell responses. A schematic representation of the cell 
populations involved  in the suppressor pathway. See text for details. 
Thus, Ts  e alone are insufficient to directly suppress CS effector cells, but must interact 
with a  third  I-J  + suppressor, termed Ts3, present in  the antigen-primed lymphocyte 
population.  The Tsa population  also  functions  in  the effector phase of the immune 
response and may represent the actual effector cell. The Tse-Ts~ interaction is restricted 
by both  H-2  and  Igh-region  genes.  These  interactions  could  occur  either  through 
direct  cell-cell contact  or,  more consistent  with  the  findings  in  other systems, via a 
soluble  suppressor  factor  (15).  The  dual  genetic  restriction  may  be  the  result  of 
combined  presentation  of anti-idiotype  along  with  Ia determinants  on  Ts  e to  Ts3. 
Alternatively, Ts  ~ (or its factor) may combine with two distinct Tsa populations, one 
via an Ia interaction, and the other via an idiotypic-anti-idiotypic interaction. 
If a  Tsa cell bears idiotypic receptors, it could form an antigen bridge with the CS 
or DTH effector T  cells, or with helper T  cells for antibody production, and transmit 
a  suppressive signal.  It  is  also  possible that  macrophages release suppressor  factors 
after involvement in  the Ts~-Ts3 interaction  (25).  However, we cannot  rule out  the 
possibility of more complex interactions involving multiple types of Ts3 subsets, some 
idiotypic,  others  anti-idiotypic,  which  may be necessary  to  account  for findings  of 
idiotype-specific suppression in some other experimental systems (24, 26, 27). 
Summary 
In  the  current  study,  we  examine  the  mechanism  of suppression  of cutaneous 
sensitivity (CS)  responses to 4-hydroxy-3-nitrophenyl acetyl succinimide ester. Intra- MARY  E.  SUNDAY, BARUJ  BENACERRAF,  AND MARTIN E,  DORF  821 
venous administration  of haptenated syngeneic spleen cells induces a state of hapten- 
specific tolerance involving 1-J-bearing suppressor T  cells that function at either the 
induction phase or the effector phase of the CS response. The effector-phase suppressor 
cells  (Ts  ~)  are  genetically  restricted  by both  Igh and  H-2 region  genes.  However, a 
third  cell  population  is  also  required  in  the  immune  lymphocyte  population  for 
immune suppression. This third cell population, termed Tsa, is an I-J  +, cyclophospha- 
mide-sensitive  T  cell,  as shown  by reconstitution  experiments.  Further,  the  Tse-Tsz 
interaction  is restricted  by genes in the H-2 and Igh gene complexes. The results are 
discussed  with  respect  to  the  pathway  of cellular  interactions  leading  to  immuno- 
suppression. 
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